Search

Your search keyword '"Park, Wungki"' showing total 329 results
Start Over Author "Park, Wungki"
329 results on '"Park, Wungki"'

1. Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival

Author

Varghese, Anna M., Perry, Maria A., Chou, Joanne F., Nandakumar, Subhiksha, Muldoon, Daniel, Erakky, Amanda, Zucker, Amanda, Fong, Christopher, Mehine, Miika, Nguyen, Bastien, Basturk, Olca, Balogun, Fiyinfolu, Kelsen, David P., Brannon, A. Rose, Mandelker, Diana, Vakiani, Efsevia, Park, Wungki, Yu, Kenneth H., Stadler, Zsofia K., Schattner, Mark A., Jarnagin, William R., Wei, Alice C., Chakravarty, Debyani, Capanu, Marinela, Schultz, Nikolaus, Berger, Michael F., Iacobuzio-Donahue, Christine A., Bandlamudi, Chaitanya, and O’Reilly, Eileen M.

Published
2025
Full Text
View/download PDF

2. Automated real-world data integration improves cancer outcome prediction

Author

Jee, Justin, Fong, Christopher, Pichotta, Karl, Tran, Thinh Ngoc, Luthra, Anisha, Waters, Michele, Fu, Chenlian, Altoe, Mirella, Liu, Si-Yang, Maron, Steven B., Ahmed, Mehnaj, Kim, Susie, Pirun, Mono, Chatila, Walid K., de Bruijn, Ino, Pasha, Arfath, Kundra, Ritika, Gross, Benjamin, Mastrogiacomo, Brooke, Aprati, Tyler J., Liu, David, Gao, JianJiong, Capelletti, Marzia, Pekala, Kelly, Loudon, Lisa, Perry, Maria, Bandlamudi, Chaitanya, Donoghue, Mark, Satravada, Baby Anusha, Martin, Axel, Shen, Ronglai, Chen, Yuan, Brannon, A. Rose, Chang, Jason, Braunstein, Lior, Li, Anyi, Safonov, Anton, Stonestrom, Aaron, Sanchez-Vela, Pablo, Wilhelm, Clare, Robson, Mark, Scher, Howard, Ladanyi, Marc, Reis-Filho, Jorge S., Solit, David B., Jones, David R., Gomez, Daniel, Yu, Helena, Chakravarty, Debyani, Yaeger, Rona, Abida, Wassim, Park, Wungki, O’Reilly, Eileen M., Garcia-Aguilar, Julio, Socci, Nicholas, Sanchez-Vega, Francisco, Carrot-Zhang, Jian, Stetson, Peter D., Levine, Ross, Rudin, Charles M., Berger, Michael F., Shah, Sohrab P., Schrag, Deborah, Razavi, Pedram, Kehl, Kenneth L., Li, Bob T., Riely, Gregory J., and Schultz, Nikolaus

Published
2024
Full Text
View/download PDF

3. Survival Outcomes and Genetic Characteristics of Resected Pancreatic Acinar Cell Carcinoma

Author

Blair, Alex B., Radomski, Shannon N., Chou, Joanne, Liu, Mengyuan, Howell, Thomas Clark, Park, Wungki, O’Reilly, Eileen M., Zheng, Lei, Balachandran, Vinod P., Wei, Alice C., Kingham, T. Peter, D’Angelica, Michael I., Drebin, Jeffrey, Zani, Sabino, Blazer, III, Dan G., Burkhart, Richard A., Burns, III, William R., Lafaro, Kelly J., Allen, Peter J., Jarnagin, William R., Lidsky, Michael E., He, Jin, and Soares, Kevin C.

Published
2024
Full Text
View/download PDF

4. Methylation Analyses Reveal Promoter Hypermethylation as a Rare Cause of “Second Hit” in Germline BRCA1-Associated Pancreatic Ductal Adenocarcinoma

Author

Zheng-Lin, Binbin, Rainone, Michael, Varghese, Anna M, Yu, Kenneth H, Park, Wungki, Berger, Michael, Mehine, Miika, Chou, Joanne, Capanu, Marinela, Mandelker, Diana, Stadler, Zsofia K, Birsoy, Ozge, Jairam, Sowmya, Yang, Ciyu, Li, Yirong, Wong, Donna, Benhamida, Jamal K, Ladanyi, Marc, Zhang, Liying, and O’Reilly, Eileen M

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Digestive Diseases, Rare Diseases, Cancer, Genetics, Pancreatic Cancer, Humans, BRCA1 Protein, Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors, Germ-Line Mutation, DNA Methylation, Promoter Regions, Genetic, Pharmacology and Pharmaceutical Sciences, Oncology & Carcinogenesis, Pharmacology & Pharmacy, Pharmacology and pharmaceutical sciences
Abstract

Background and objectivePancreatic ductal adenocarcinoma (PDAC) is characterized by the occurrence of pathogenic variants in BRCA1/2 in 5-6% of patients. Biallelic loss of BRCA1/2 enriches for response to platinum agents and poly (ADP-ribose) polymerase 1 inhibitors. There is a dearth of evidence on the mechanism of inactivation of the wild-type BRCA1 allele in PDAC tumors with a germline BRCA1 (gBRCA1) pathogenic or likely pathogenic variant (P/LPV). Herein, we examine promotor hypermethylation as a "second hit" mechanism in patients with gBRCA1-PDAC.MethodsWe evaluated patients with PDAC who underwent Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) somatic and germline testing from an institutional database. DNA isolated from tumor tissue and matched normal peripheral blood were sequenced by MSK-IMPACT. In patients with gBRCA1-PDAC, we examined the somatic BRCA1 mutation status and promotor methylation status of the tumor BRCA1 allele via a methylation array analysis. In patients with sufficient remaining DNA, a second methylation analysis by pyrosequencing was performed.ResultsOf 1012 patients with PDAC, 19 (1.9%) were identified to harbor a gBRCA1 P/LPV. Fifteen patients underwent a methylation array and the mean percentage of BRCA1 promotor methylation was 3.62%. In seven patients in whom sufficient DNA was available, subsequent pyrosequencing confirmed an unmethylated BRCA1 promotor. Loss of heterozygosity was detected in 12 of 19 (63%, 95% confidence interval 38-84) patients, demonstrating loss of heterozygosity is the major molecular mechanism of BRCA1 inactivation in PDAC. Two (10.5%) cases had a somatic BRCA1 mutation.ConclusionsIn patients with gBRCA1-P/LPV-PDAC, loss of heterozygosity is the main inactivating mechanism of the wild-type BRCA1 allele in the tumor, and methylation of the BRCA1 promoter is a distinctly uncommon occurrence.

Published
2022

6. SWI/SNF Complex-Deficient Undifferentiated Carcinoma of the Pancreas: Clinicopathologic and Genomic Analysis

Author

Yavas, Aslihan, Ozcan, Kerem, Adsay, N. Volkan, Balci, Serdar, Tarcan, Zeynep C., Hechtman, Jaclyn F., Luchini, Claudio, Scarpa, Aldo, Lawlor, Rita T., Mafficini, Andrea, Reid, Michelle D., Xue, Yue, Yang, Zhaohai, Haye, Kester, Bellizzi, Andrew M., Vanoli, Alessandro, Benhamida, Jamal, Balachandran, Vinod, Jarnagin, William, Park, Wungki, O’Reilly, Eileen M., Klimstra, David S., and Basturk, Olca

Published
2024
Full Text
View/download PDF

7. Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer

Author

McIntyre, Caitlin A., Grimont, Adrien, Park, Jiwoon, Meng, Yinuo, Sisso, Whitney J., Seier, Kenneth, Jang, Gun Ho, Walch, Henry, Aveson, Victoria G., Falvo, David J., Fall, William B., Chan, Christopher W., Wenger, Andrew, Ecker, Brett L., Pulvirenti, Alessandra, Gelfer, Rebecca, Zafra, Maria Paz, Schultz, Nikolaus, Park, Wungki, O’Reilly, Eileen M., Houlihan, Shauna L., Alonso, Alicia, Hissong, Erika, Church, George M., Mason, Christopher E., Siolas, Despina, Notta, Faiyaz, Gonen, Mithat, Dow, Lukas E., Jarnagin, William R., and Chandwani, Rohit

Published
2024
Full Text
View/download PDF

10. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer

Author

Rojas, Luis A., Sethna, Zachary, Soares, Kevin C., Olcese, Cristina, Pang, Nan, Patterson, Erin, Lihm, Jayon, Ceglia, Nicholas, Guasp, Pablo, Chu, Alexander, Yu, Rebecca, Chandra, Adrienne Kaya, Waters, Theresa, Ruan, Jennifer, Amisaki, Masataka, Zebboudj, Abderezak, Odgerel, Zagaa, Payne, George, Derhovanessian, Evelyna, Müller, Felicitas, Rhee, Ina, Yadav, Mahesh, Dobrin, Anton, Sadelain, Michel, Łuksza, Marta, Cohen, Noah, Tang, Laura, Basturk, Olca, Gönen, Mithat, Katz, Seth, Do, Richard Kinh, Epstein, Andrew S., Momtaz, Parisa, Park, Wungki, Sugarman, Ryan, Varghese, Anna M., Won, Elizabeth, Desai, Avni, Wei, Alice C., D’Angelica, Michael I., Kingham, T. Peter, Mellman, Ira, Merghoub, Taha, Wolchok, Jedd D., Sahin, Ugur, Türeci, Özlem, Greenbaum, Benjamin D., Jarnagin, William R., Drebin, Jeffrey, O’Reilly, Eileen M., and Balachandran, Vinod P.

Published
2023
Full Text
View/download PDF

12. Concordance in Oncogenic Alterations Between the Primary Tumor and Advanced Disease: Insights Into the Heterogeneity of Intrahepatic Cholangiocarcinoma

Author

McIntyre, Sarah M., Preston, William A., Walch, Henry, Sharib, Jeremy, Kundra, Ritika, Sigel, Carlie, Lidsky, Michael E., Allen, Peter J., Morse, Michael A., Chen, Wei, Cercek, Andrea, Harding, James J., Abou-Alfa, Ghassan K., OʼReilly, Eileen M., Park, Wungki, Balachandran, Vinod P., Drebin, Jeffrey, Soares, Kevin C., Wei, Alice, Kingham, T. Peter, DʼAngelica, Michael I., Iacobuzio-Donahue, Christine, and Jarnagin, William R.

Published
2024
Full Text
View/download PDF

14. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

Author

Bedognetti, Davide, Ceccarelli, Michele, Galluzzi, Lorenzo, Lu, Rongze, Palucka, Karolina, Samayoa, Josue, Spranger, Stefani, Warren, Sarah, Wong, Kwok-Kin, Ziv, Elad, Chowell, Diego, Coussens, Lisa M, De Carvalho, Daniel D, DeNardo, David G, Galon, Jérôme, Kaufman, Howard L, Kirchhoff, Tomas, Lotze, Michael T, Luke, Jason J, Minn, Andy J, Politi, Katerina, Shultz, Leonard D, Simon, Richard, Thórsson, Vésteinn, Weidhaas, Joanne B, Ascierto, Maria Libera, Ascierto, Paolo Antonio, Barnes, James M, Barsan, Valentin, Bommareddy, Praveen K, Bot, Adrian, Church, Sarah E, Ciliberto, Gennaro, De Maria, Andrea, Draganov, Dobrin, Ho, Winson S, McGee, Heather M, Monette, Anne, Murphy, Joseph F, Nisticò, Paola, Park, Wungki, Patel, Maulik, Quigley, Michael, Radvanyi, Laszlo, Raftopoulos, Harry, Rudqvist, Nils-Petter, Snyder, Alexandra, Sweis, Randy F, Valpione, Sara, Zappasodi, Roberta, Butterfield, Lisa H, Disis, Mary L, Fox, Bernard A, Cesano, Alessandra, and Marincola, Francesco M

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Cancer, Women's Health, Human Genome, Genetics, 2.1 Biological and endogenous factors, 1.1 Normal biological development and functioning, Generic health relevance, Good Health and Well Being, Advisory Committees, Animals, Biomarkers, Tumor, Congresses as Topic, Disease Models, Animal, Humans, Immunotherapy, Medical Oncology, Neoplasms, Societies, Medical, Treatment Outcome, Tumor Microenvironment, Cancer immune responsiveness, Immune checkpoint inhibitor, Immune oncology, Tumor microenvironment, Tumor mutational burden, Immunogenic cell death, Biomarker, Germline molecular alterations, Somatic molecular alterations, Cancer immune phenotype, Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups, Oncology and carcinogenesis
Abstract

Tumor immunology has changed the landscape of cancer treatment. Yet, not all patients benefit as cancer immune responsiveness (CIR) remains a limitation in a considerable proportion of cases. The multifactorial determinants of CIR include the genetic makeup of the patient, the genomic instability central to cancer development, the evolutionary emergence of cancer phenotypes under the influence of immune editing, and external modifiers such as demographics, environment, treatment potency, co-morbidities and cancer-independent alterations including immune homeostasis and polymorphisms in the major and minor histocompatibility molecules, cytokines, and chemokines. Based on the premise that cancer is fundamentally a disorder of the genes arising within a cell biologic process, whose deviations from normality determine the rules of engagement with the host's response, the Society for Immunotherapy of Cancer (SITC) convened a task force of experts from various disciplines including, immunology, oncology, biophysics, structural biology, molecular and cellular biology, genetics, and bioinformatics to address the complexity of CIR from a holistic view. The task force was launched by a workshop held in San Francisco on May 14-15, 2018 aimed at two preeminent goals: 1) to identify the fundamental questions related to CIR and 2) to create an interactive community of experts that could guide scientific and research priorities by forming a logical progression supported by multiple perspectives to uncover mechanisms of CIR. This workshop was a first step toward a second meeting where the focus would be to address the actionability of some of the questions identified by working groups. In this event, five working groups aimed at defining a path to test hypotheses according to their relevance to human cancer and identifying experimental models closest to human biology, which include: 1) Germline-Genetic, 2) Somatic-Genetic and 3) Genomic-Transcriptional contributions to CIR, 4) Determinant(s) of Immunogenic Cell Death that modulate CIR, and 5) Experimental Models that best represent CIR and its conversion to an immune responsive state. This manuscript summarizes the contributions from each group and should be considered as a first milestone in the path toward a more contemporary understanding of CIR. We appreciate that this effort is far from comprehensive and that other relevant aspects related to CIR such as the microbiome, the individual's recombined T cell and B cell receptors, and the metabolic status of cancer and immune cells were not fully included. These and other important factors will be included in future activities of the taskforce. The taskforce will focus on prioritization and specific actionable approach to answer the identified questions and implementing the collaborations in the follow-up workshop, which will be held in Houston on September 4-5, 2019.

Published
2019

15. Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

Author

Bedognetti, Davide, Ceccarelli, Michele, Galluzzi, Lorenzo, Lu, Rongze, Palucka, Karolina, Samayoa, Josue, Spranger, Stefani, Warren, Sarah, Wong, Kwok-Kin, Ziv, Elad, Chowell, Diego, Coussens, Lisa M, De Carvalho, Daniel D, DeNardo, David G, Galon, Jérôme, Kaufman, Howard L, Kirchhoff, Tomas, Lotze, Michael T, Luke, Jason J, Minn, Andy J, Politi, Katerina, Shultz, Leonard D, Simon, Richard, Thórsson, Vésteinn, Weidhaas, Joanne B, Ascierto, Maria Libera, Ascierto, Paolo Antonio, Barnes, James M, Barsan, Valentin, Bommareddy, Praveen K, Bot, Adrian, Church, Sarah E, Ciliberto, Gennaro, De Maria, Andrea, Draganov, Dobrin, Ho, Winson S, McGee, Heather M, Monette, Anne, Murphy, Joseph F, Nisticò, Paola, Park, Wungki, Patel, Maulik, Quigley, Michael, Radvanyi, Laszlo, Raftopoulos, Harry, Rudqvist, Nils-Petter, Snyder, Alexandra, Sweis, Randy F, Valpione, Sara, Zappasodi, Roberta, Butterfield, Lisa H, Disis, Mary L, Fox, Bernard A, Cesano, Alessandra, and Marincola, Francesco M

Subjects
Biomedical and Clinical Sciences, Immunology, Cancer, Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups, Oncology and carcinogenesis
Abstract

Following publication of the original article [1], the author reported that an author name, Roberta Zappasodi, was missed in the authorship list.

Published
2019

18. Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer.

Author

O'Connor, Catherine A., Harrold, Emily, Lin, David, Walch, Henry, Gazzo, Andrea, Ranganathan, Megha, Kane, Sarah, Keane, Fergus, Schoenfeld, Joshua, Moss, Drew, Thurtle-Schmidt, Deborah M., Suehnholz, Sarah P., Chakravarty, Debyani, Balogun, Fiyinfolu, Varghese, Anna, Yu, Kenneth, Kelsen, David, Latham, Alicia, Weigelt, Britta, and Park, Wungki

Published
2024
Full Text
View/download PDF

19. Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics

Author

Mezquita, Laura, Preeshagul, Isabel, Auclin, Edouard, Saravia, Diana, Hendriks, Lizza, Rizvi, Hira, Park, Wungki, Nadal, Ernest, Martin-Romano, Patricia, Ruffinelli, Jose C., Ponce, Santiago, Audigier-Valette, Clarisse, Carnio, Simona, Blanc-Durand, Felix, Bironzo, Paolo, Tabbò, Fabrizio, Reale, Maria Lucia, Novello, Silvia, Hellmann, Matthew D., Sawan, Peter, Girshman, Jeffrey, Plodkowski, Andrew J., Zalcman, Gerard, Majem, Margarita, Charrier, Melinda, Naigeon, Marie, Rossoni, Caroline, Mariniello, AnnaPaola, Paz-Ares, Luis, Dingemans, Anne Marie, Planchard, David, Cozic, Nathalie, Cassard, Lydie, Lopes, Gilberto, Chaput, Nathalie, Arbour, Kathryn, and Besse, Benjamin

Published
2021
Full Text
View/download PDF

21. Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC).

Author

Garrido-Laguna, Ignacio, Wolpin, Brian M., Park, Wungki, Azad, Nilofer Saba, Spira, Alexander I., Starodub, Alexander, Sommerhalder, David, Punekar, Salman Rafi, Herzberg, Benjamin, Barve, Minal A., Pelster, Meredith, Valerin, Jennifer Brooke, Hecht, Joel R, Vora, Rashmi, Hegde, Aparna Madhukeshwar, Gustafson, Clay, Tao, Lin, Kar, Sumit, Lin, Kevin K., and Hong, David S.

Published
2025
Full Text
View/download PDF

22. Clinical landscape of cell free DNA alterations in patients with advanced biliary tract cancer treated with targeted therapies.

Author

Thummalapalli, Rohit, Darmofal, Maidson, Seier, Kenneth, Khalil, Danny N., Walch, Henry S., Shia, Jinru, Park, Wungki, El Dika, Imane H., Chatila, Walid Khaled, Schultz, Nikolaus, Alice, Wei, Cercek, Andrea, O'Reilly, Eileen M., Solit, David B., Gonen, Mithat, Berger, Michael F., Abou-Alfa, Ghassan K., Jarnagin, William R., Cowzer, Darren, and Harding, James J.

Published
2025
Full Text
View/download PDF

23. Molecular and clinical determinants of targeted therapy (TT) outcomes in biliary tract cancer (BTC): Analysis of a prospectively maintained next generation sequencing (NGS) biorepository.

Author

Cowzer, Darren, Walch, Henry S., Atri, Pranita, Shah, Farheen, Huq, Risha, Khalil, Danny N., Park, Wungki, Yeh, Randy, Do, Richard K. G., Basturk, Olca, Shia, Jinru, Berger, Michael F., O'Reilly, Eileen M., Jarnagin, William R., Schultz, Nikolaus, Gonen, Mithat, Solit, David B., Abou-Alfa, Ghassan K., Chatila, Walid Khaled, and Harding, James J.

Published
2025
Full Text
View/download PDF

27. Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease.

Author

Keane, Fergus, Chou, Joanne F, Walch, Henry, Schoenfeld, Joshua, Singhal, Anupriya, Cowzer, Darren, Harrold, Emily, O'Connor, Catherine A, Park, Wungki, Varghese, Anna, Dika, Imane El, Balogun, Fiyinfolu, Yu, Kenneth H, Capanu, Marinela, Schultz, Nikolaus, Yaeger, Rona, and O'Reilly, Eileen M

Subjects
PANCREATIC duct, PANCREATIC cancer, RAS oncogenes, BODY mass index, OVERALL survival
Abstract

Background Mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) is the most common oncogene alteration in pancreatic ductal adenocarcinoma, and KRAS glycine to cystine substitution at codon 12 (G12C) mutations (KRAS G12Cmut) are observed in 1%-2%. Several inhibitors of KRAS G12C have recently demonstrated promise in solid tumors, including pancreatic cancer. Little is known regarding clinical, genomics, and outcome data of this population. Methods Patients with pancreatic cancer and KRAS G12Cmut were identified at Memorial Sloan Kettering Cancer Center and via the American Association of Cancer Research Project Genomics, Evidence, Neoplasia, Information, Exchange database. Clinical, treatment, genomic, and outcomes data were analyzed. A cohort of patients at Memorial Sloan Kettering Cancer Center with non-G12C KRAS pancreatic cancer was included for comparison. Results Among 3571 patients with pancreatic ductal adenocarcinoma, 39 (1.1%) with KRAS G12Cmut were identified. Median age was 67 years, and 56% were female. Median body mass index was 29.2 kg/m2, and 67% had a smoking history. Median overall survival was 13 months (95% CI: 9.4 months, not reached) for stage IV and 26 months (95% CI: 23 months, not reached) for stage I-III. Complete genomic data (via American Association of Cancer Research Project Genomics, Evidence, Neoplasia, Information, Exchange database) was available for 74 patients. Most common co-alterations included TP53 (73%), CDKN2A (33%), SMAD4 (28%), and ARID1A (21%). Compared with a large cohort (n = 2931) of non-G12C KRAS- mutated pancreatic ductal adenocarcinoma, ARID1A co-mutations were more frequent in KRAS G12Cmut (P  < .05). Overall survival did not differ between KRAS G12Cmut and non-G12C KRAS pancreatic ductal adenocarcinoma. Germline pathogenic variants were identified in 17% of patients; 2 patients received KRAS G12C-directed therapy. Conclusion Pancreatic cancer and KRAS G12Cmut may be associated with a distinct clinical phenotype. Genomic features are similar to non-G12C KRAS- mutated pancreatic cancer, although enrichment of ARID1A co-mutations was observed. Targeting of KRAS G12C in pancreatic cancer provides a precedent for broader KRAS targeting in pancreatic cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort

Author

Naqash, Abdul Rafeh, Ricciuti, Biagio, Owen, Dwight H., Florou, Vaia, Toi, Yukihiro, Cherry, Cynthia, Hafiz, Maida, De Giglio, Andrea, Muzaffar, Mavish, Patel, Sandip H., Sugawara, Shunichi, Burkart, Jarred, Park, Wungki, Chiari, Rita, Sugisaka, Jun, Otterson, Gregory A., de Lima Lopes, Gilberto, and Walker, Paul R.

Published
2020
Full Text
View/download PDF

31. Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer

Author

Chae, Young Kwang, Viveiros, Pedro, Lopes, Gilberto, Sukhadia, Bhoomika, Sheikh, Muhammad Mubbashir, Saravia, Diana, Florou, Vaia, Sokol, Ethan S., Frampton, Garrett M., Chalmers, Zachary R., Ali, Siraj M., Ross, Jeffrey S., Chang, Sangmin, Wang, Si, Chiec, Lauren, Rahbari, Ashkon, Mohindra, Nisha, Villaflor, Victoria, Shin, Sang Ha, Oh, Michael, Anker, Jonathan, Park, Lee Chun, Wang, Victor, Chuang, Jeffrey, and Park, Wungki

Published
2019
Full Text
View/download PDF

34. BNT321, a novel monoclonal antibody targeting sialyl Lewis A: Phase 1 monotherapy and combination with mFOLFIRINOX in patients with advanced CA19-9 expressing cancers.

Author

O'Reilly, Eileen Mary, primary, Bauer, Todd Michael, additional, Borazanci, Erkut Hasan, additional, Pelster, Meredith, additional, Varghese, Anna M., additional, Park, Wungki, additional, Patel, Manish R., additional, Jameson, Gayle S., additional, Larsen, Mary, additional, Chin, Kathryn, additional, Melink, Teresa J., additional, Gutheil, John, additional, Cosgrove, Elizabeth O'Reilly, additional, Balogh, Kristen N., additional, Maiwald, Tim, additional, DeMario, Mark, additional, Celik, Ilhan, additional, Türeci, Özlem, additional, Sahin, Ugur, additional, and Wang, Judy S., additional

Published
2024
Full Text
View/download PDF

35. Intrahepatic cholangiocarcinoma: Recurrence patterns, genomics and survival.

Author

Chandra, Pratik, primary, Song, Yi, additional, Drill, Esther N., additional, Wei, Alice Chia-Chi, additional, Kemeny, Nancy E., additional, Cercek, Andrea, additional, Connell, Louise Catherine, additional, Harding, James J., additional, Abou-Alfa, Ghassan K., additional, Park, Wungki, additional, Kingham, T. Peter, additional, Soares, Kevin, additional, Balachandran, Vinod P., additional, Drebin, Jeffrey A., additional, D'Angelica, Michael Ian, additional, O'Reilly, Eileen Mary, additional, Groot Koerkamp, Bas, additional, and Jarnagin, William R., additional

Published
2024
Full Text
View/download PDF

36. Abstract B042: Clinical and molecular characterization of Lynch syndrome-associated pancreas adenocarcinoma (PDAC)

Author

Harrold, Emily, primary, O'Connor, Catherine A., additional, Lin, David, additional, Gazzo, Andrea, additional, Walch, Henry, additional, Ranganathan, Megha, additional, Catchings, Amanda, additional, Kane, Sarah, additional, Keane, Fergus, additional, Thurtle-Schmidt, Deborah M., additional, Balogun, Fiyinfolu, additional, Varghese, Anna, additional, Yu, Kenneth, additional, Kelsen, David, additional, Latham, Alicia, additional, Weigelt, Britta, additional, Park, Wungki, additional, Stadler, Zsofia, additional, and O'Reilly, Eileen M., additional

Published
2024
Full Text
View/download PDF

37. Abstract C104: Dual primary pancreas cancers – Related or independent lesions?

Author

Schoenfeld, Joshua D., primary, Sahan-Ozkan, Hulya, additional, Bilani, Nadeem, additional, D'Angelica, Michael I., additional, Jarnagin, William R., additional, Drebin, Jeffrey, additional, Reidy-Lagunes, Diane, additional, Wei, Alice C., additional, Chalasani, Sree B., additional, Varghese, Anna M., additional, Balogun, Fiyinfolu, additional, Park, Wungki, additional, Yu, Kenneth H., additional, Basturk, Olca, additional, and O'Reilly, Eileen M., additional

Published
2024
Full Text
View/download PDF

38. Abstract C074: Clinico-genomic characterization of N=2,460 pancreatic adenocarcinoma identifies KRASMUT dosage as prognostic of overall survival across disease stages

Author

Varghese, Anna M., primary, Perry, Maria A., additional, Muldoon, Daniel, additional, Nandakumar, Subhiksha, additional, Erakky, Amanda, additional, Nguyen, Bastien, additional, Zucker, Amanda, additional, Ozkan, Hulya Sahin, additional, Basturk, Olca, additional, Chakravarty, Debyani, additional, Kelsen, David P., additional, Park, Wungki, additional, Yu, Kenneth H., additional, Wei, Alice C., additional, Schultz, Nikolaus, additional, Berger, Michael F., additional, Iacobuzio-Donahue, Christine, additional, Bandlamudi, Chaitanya, additional, and O'Reilly, Eileen M., additional

Published
2024
Full Text
View/download PDF

39. Salvage Ablative Radiotherapy for Isolated Local Recurrence of Pancreatic Adenocarcinoma following Definitive Surgery.

Author

Dee, Edward Christopher, Ng, Victor C., O'Reilly, Eileen M., Wei, Alice C., Lobaugh, Stephanie M., Varghese, Anna M., Zinovoy, Melissa, Romesser, Paul B., Wu, Abraham J., Hajj, Carla, Cuaron, John J., Khalil, Danny N., Park, Wungki, Yu, Kenneth H., Zhang, Zhigang, Drebin, Jeffrey A., Jarnagin, William R., Crane, Christopher H., and Reyngold, Marsha

Subjects
ADENOCARCINOMA, CHEMORADIOTHERAPY, PANCREATIC surgery, RADIOTHERAPY, SURGICAL excision, OVERALL survival, RADIATION doses
Abstract

Introduction: The rate of isolated locoregional recurrence after surgery for pancreatic adenocarcinoma (PDAC) approaches 25%. Ablative radiation therapy (A-RT) has improved outcomes for locally advanced disease in the primary setting. We sought to evaluate the outcomes of salvage A-RT for isolated locoregional recurrence and examine the relationship between subsequent patterns of failure, radiation dose, and treatment volume. Methods: We conducted a retrospective analysis of all consecutive participants who underwent A-RT for an isolated locoregional recurrence of PDAC after prior surgery at our institution between 2016 and 2021. Treatment consisted of ablative dose (BED10 98–100 Gy) to the gross disease with an additional prophylactic low dose (BED10 < 50 Gy), with the elective volume covering a 1.5 cm isotropic expansion around the gross disease and the circumference of the involved vessels. Local and locoregional failure (LF and LRF, respectively) estimated by the cumulative incidence function with competing risks, distant metastasis-free and overall survival (DMFS and OS, respectively) estimated by the Kaplan–Meier method, and toxicities scored by CTCAE v5.0 are reported. Location of recurrence was mapped to the dose region on the initial radiation plan. Results: Among 65 participants (of whom two had two A-RT courses), the median age was 67 (range 37–87) years, 36 (55%) were male, and 53 (82%) had undergone pancreaticoduodenectomy with a median disease-free interval to locoregional recurrence of 16 (range, 6–71) months. Twenty-seven participants (42%) received chemotherapy prior to A-RT. With a median follow-up of 35 months (95%CI, 26–56 months) from diagnosis of recurrence, 24-month OS and DMFS were 57% (95%CI, 46–72%) and 22% (95%CI, 14–37%), respectively, while 24-month cumulative incidence of in-field LF and total LRF were 28% (95%CI, 17–40%) and 36% (95%CI 24–48%), respectively. First failure after A-RT was distant in 35 patients (53.8%), locoregional in 12 patients (18.5%), and synchronous distant and locoregional in 10 patients (15.4%). Most locoregional failures occurred in elective low-dose volumes. Acute and chronic grade 3–4 toxicities were noted in 1 (1.5%) and 5 patients (7.5%), respectively. Conclusions: Salvage A-RT achieves favorable OS and local control outcomes in participants with an isolated locoregional recurrence of PDAC after surgical resection. Consideration should be given to extending high-dose fields to include adjacent segments of at-risk vessels beyond direct contact with the gross disease. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

40. Local Control and Survival After Induction Chemotherapy and Ablative Radiation Versus Resection for Pancreatic Ductal Adenocarcinoma With Vascular Involvement

Author

Jolissaint, Joshua S., Reyngold, Marsha, Bassmann, Jared, Seier, Kenneth P., Gönen, Mithat, Varghese, Anna M., Yu, Kenneth H., Park, Wungki, O’Reilly, Eileen M., Balachandran, Vinod P., D’Angelica, Michael I., Drebin, Jeffrey A., Kingham, T. Peter, Soares, Kevin C., Jarnagin, William R., Crane, Christopher H., and Wei, Alice C.

Published
2021
Full Text
View/download PDF

41. Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell Carcinoma

Author

Mandelker, Diana, primary, Marra, Antonio, additional, Zheng-Lin, Binbin, additional, Selenica, Pier, additional, Blanco-Heredia, Juan, additional, Zhu, Yingjie, additional, Gazzo, Andrea, additional, Wong, Donna, additional, Yelskaya, Zarina, additional, Rai, Vikas, additional, Somar, Joshua, additional, Ostafi, Silvana, additional, Mehta, Nikita, additional, Yang, Ciyu, additional, Li, Yirong, additional, Brown, David N., additional, da Silva, Edaise M., additional, Pei, Xin, additional, Linkov, Irina, additional, Terraf, Panieh, additional, Misyura, Maksym, additional, Ceyhan-Birsoy, Ozge, additional, Ladanyi, Marc, additional, Berger, Michael, additional, Pareja, Fresia, additional, Stadler, Zsofia, additional, Offit, Kenneth, additional, Riaz, Nadeem, additional, Park, Wungki, additional, Chou, Joanne, additional, Capanu, Marinela, additional, Koehler, Maria, additional, Rosen, Ezra, additional, O'Reilly, Eileen M., additional, and Reis-Filho, Jorge S., additional

Published
2023
Full Text
View/download PDF

43. Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden

Author

Florou, Vaia, primary, Floudas, Charalampos S, additional, Maoz, Asaf, additional, Naqash, Abdul Rafeh, additional, Norton, Carter, additional, Tan, Aik Choon, additional, Sokol, Ethan S, additional, Frampton, Garrett, additional, Soares, Heloisa P, additional, Puri, Sonam, additional, Swami, Umang, additional, Wilky, Breelyn, additional, Hosein, Peter, additional, Trent, Jonathan, additional, Lopes, Gilberto de Lima, additional, Park, Wungki, additional, and Garrido-Laguna, Ignacio, additional

Published
2023
Full Text
View/download PDF

47. Salvage hepatic artery infusion chemotherapy after first-line systemic failure in patients with unresectable cholangiocarcinoma.

Author

Nasar, Naaz, Armstrong, Misha, Chou, Joanne F., Gonen, Mithat, Soares, Kevin, Balachandran, Vinod P., Drebin, Jeffrey A., Kingham, T. Peter, Wei, Alice Chia-Chi, D'Angelica, Michael Ian, Cercek, Andrea, Harding, James J., O'Reilly, Eileen Mary, Abou-Alfa, Ghassan K., Park, Wungki, Connell, Louise Catherine, Kemeny, Nancy E., and Jarnagin, William R.

Published
2024
Full Text
View/download PDF

48. Abstract 6421: Molecular profiles and single cell analysis identify immunogenic pancreatic ductal adenocarcinoma (iPDAC)

Author

Park, Wungki, primary, O'Connor, Catherine, additional, Umeda, Shigeaki, additional, Sharma, Roshan, additional, Zhu, Yingjie, additional, Karnoub, Elias-Ramzey, additional, Varghese, Anna, additional, Soares, Kevin C., additional, Jimemez, Alejandro, additional, Yavas, Asli, additional, Yu, Kenneth H., additional, Vinod, Balachandran P., additional, Chou, Joanne F., additional, Khalil, Danny N., additional, David, Kelsen, additional, Ozkan, Hulya Sahin, additional, Basturk, Olca, additional, Capanu, Marinela, additional, Nawy, Tal, additional, Berger, Michael F., additional, Abou-Alfa, Ghassan K., additional, Reis-Filho, Jorge S., additional, Chaligne, Ronan, additional, Riaz, Nadeem, additional, Pe'er, Dana, additional, Iacobuzio-Donahue, Christine, additional, and O'Reilly, Eileen M., additional

Published
2023
Full Text
View/download PDF

49. Data from Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice

Author

Park, Wungki, primary, O'Connor, Catherine A., primary, Bandlamudi, Chaitanya, primary, Forman, Daniella, primary, Chou, Joanne F., primary, Umeda, Shigeaki, primary, Reyngold, Marsha, primary, Varghese, Anna M., primary, Keane, Fergus, primary, Balogun, Fiyinfolu, primary, Yu, Kenneth H., primary, Kelsen, David P., primary, Crane, Christopher, primary, Capanu, Marinela, primary, Iacobuzio-Donahue, Christine, primary, and O'Reilly, Eileen M., primary

Published
2023
Full Text
View/download PDF

50. Supplementary Figure from Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice

Author

Park, Wungki, primary, O'Connor, Catherine A., primary, Bandlamudi, Chaitanya, primary, Forman, Daniella, primary, Chou, Joanne F., primary, Umeda, Shigeaki, primary, Reyngold, Marsha, primary, Varghese, Anna M., primary, Keane, Fergus, primary, Balogun, Fiyinfolu, primary, Yu, Kenneth H., primary, Kelsen, David P., primary, Crane, Christopher, primary, Capanu, Marinela, primary, Iacobuzio-Donahue, Christine, primary, and O'Reilly, Eileen M., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results